eFFECTOR Therapeutics nabs $40 mln Series B

By Iris Dorbian — 2 months ago

San Diego-based eFFECTOR Therapeutics, a biopharmaceutical company focused on treating cancer, has raised $40 million in Series B funding. The investors were Altitude Life Science Ventures, AbbVie Biotech Ventures, BioMed Ventures, Abingworth, Novartis Venture Fund, SR One, The Column Group, US Venture Partners, Astellas Ventures, Osage University Partners and Mission Bay Capital. In addition to the funding, eFFECTOR has named Dave Maki, managing partner of Altitude Life Science Ventures, to its board of directors.

Continue

Dr. Shelley Chu joins Abingworth

By Luisa Beltran — 4 months ago

Abingworth said Monday that Shelley Chu MD, PhD has joined Abingworth as a Partner. Chu was previously with Gilead Sciences where she led Business Development in Oncology, Immunotherapy and Hepatitis B, as well as R&D Strategy.

Continue

Gynesonics pulls in $43 mln

By Iris Dorbian — 7 months ago

Redwood City, California-based Gynesonics, a women’s healthcare company focused on developing solutions for treating uterine fibroids, has secured $43 million in funding. Endeavour Vision and Abingworth led the round with participation from HealthCrest, InterWest Partners, Advanced Technology Ventures, HBM Partners, Correlation Ventures and Hercules Technology Growth Capital.

Continue

Chiasma snags $70 mln Series E

By Iris Dorbian — 12 months ago

Chiasma Inc has received $70 million in Series E financing. The investors included Rock Springs Capital, Sofinnova Ventures, MPM Capital, F2 Capital, 7 Med Health Ventures, Abingworth and ARCH Venture Partners. Headquartered in Newton, Massachusetts and Jerusalem, Chiasma is a biopharmaceutical firm focused on treating acromegaly.

Continue

Abingworth names von Emster a partner

By Luisa Beltran — 1 year ago

Abingworth said Friday that Kurt von Emster was named a partner effective January 5th. He will be based in Menlo Park and will help source and manage deals in early-stage and late-stage venture capital, venture growth and public market investments including VIPEs. London-based Abingworth is an investment group that focuses on life sciences and healthcare.

Continue

Abingworth promotes Ken Haas and Vin Miles to partners

By Angela Sormani — 2 years ago

Abingworth has promoted Ken Haas and Vin Miles to partners. They are both based in the US where they source and manage deals including early stage and late stage venture capital, venture growth and public market investments as well as VIPEs (venture investments in public equities).

Continue

Pixium Vision launches IPO on Euronext Paris

By Angela Sormani — 2 years ago

Pixium Vision has launched its Initial Public Offering on Euronext’s regulated market in Paris. Based in Paris, Pixium is a maker of vision restoration systems for the blind. Its backers include Sofinnova Partners, Omnes Capital, Abingworth, Global Life Sciences Ventures, Bpifrance, Seventure and Polytechnos.

Continue

Proteon Therapeutics grabs $45 mln Series D

By Iris Dorbian — 2 years ago

Proteon Therapeutics said Friday that it has raised $45 million in Series D financing. Abingworth led the round with participation from Deerfield Management Company, Pharmstandard International S.A., TVM Capital, Prism VentureWorks, Skyline Ventures, Intersouth Partners, MPM Capital, Devon Park Bioventures, Bessemer Venture Partners and the Vectis Healthcare and Life Sciences Fund. In addition to the funding, Tim Haines, a partner at Abingworth, and Dmitry Kobyzev, an investment manager at Inbio Ventures, have been added to Proteon Therapeutics’ board of directors. Headquartered in Waltham, Mass., Proteon Therapeutics is a biopharmaceutical firm focused on treating kidney and vascular diseases.

Continue

Pixium hires new CEO and director

By Iris Dorbian — 2 years ago

Pixium has appointed Khalid Ishaque as CEO and director. Previously, Ishaque worked at Boston Scientific where he most recently served as general manager of its neuromodulation international business. Based in Paris, Pixium is a maker of vision restoration systems for the blind. Its backers include Sofinnova Partners, Omnes Capital, Abingworth, Global Life Sciences Ventures, Bpifrance, Seventure and Polytechnos.

Continue

Pixium Vision raises funds led by Sofinnova

By Angela Sormani — 2 years ago

Pixium Vision, a developer of innovative retinal implant systems, has closed a Series A extension financing. This round was led by Sofinnova Partners, with support from Bpifrance, through the InnoBio fund, and existing series A investors Omnes Capital and Abingworth. In conjunction with the financing, Antoine Papiernik at Sofinnova Partners and Chahra Louafi at Bpifrance have joined the Pixium board of directors.

Continue

eFFECTOR Therapeutics Raises $45 Million Series A

By Angela Sormani — 3 years ago

Biopharmaceutical company eFFECTOR Therapeutics has completed a $45 million Series A financing. Investors include U.S. Venture Partners, Abingworth, Novartis Venture Funds, SR One, Astellas Venture Management, Osage University Partners and Mission Bay Capital.

Continue

Avedro Completes $43m Series D

By Angela Sormani — 3 years ago

Avedro has completed a $43 million Series D financing led by Abingworth along with a significant investment by Third Point. Avedro’s other investors include Prism Venture Works, De Novo Ventures, Flagship Ventures, Aperture Ventures, SCP Vitalife Partners, Borealis Ventures and Echelon Ventures. As part of the transaction, David Mayer from Abingworth and Jason Hong, PhD from Third Point will be joining the board of directors.

Continue

Labcyte Closes $5.3m Financing

By Angela Sormani — 3 years ago

Labcyte, a privately-held company advancing acoustic liquid handling, has closed a Series D financing led by the healthymagination fund, a part of GE Ventures. The $5.3 million round also included current Labcyte investors – Abingworth, Alloy Ventures, Cross Atlantic Partners, Delphi Ventures, H&Q Healthcare Investors and H&Q Life Sciences Investors.

Continue